Shire Pharmaceuticals' share price dropped sharply on August 5,after it revealed that an explosion at the US manufacturing facility of Arenol, which supplies active ingredients for its attention deficit treatments Adderall and DextroStat, would affect supplies. The company is talking with the US Food and Drug Administration to gain permission either to restart production at Arenol or transfer permits, quotas and agreements to an alternative facility. The two products account for 63% of Shire's revenues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze